Video

Dr. Logan Discusses Ibrutinib Plus Venetoclax in CLL

Author(s):

Aaron Logan, MD, PhD

In Partnership With:

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Results from the TAP CLARITY study showed that the ibrutinib plus venetoclax elicited a complete response (CR) or CR with incomplete hematologic recovery (CRi) rate of 47% for patients with relapsed/refractory CLL. Patients in the relapsed/refractory cohort achieved minimal residual disease (MRD) negativity after 1 year of combination targeted therapy.

Although the numbers are small, it looks like there are good responses, with all patients eventually developing MRD negativity with the combination of Bruton's tyrosine kinase (BTK) inhibition and BCL-2 inhibition. Logan says that he is not sure this combination will achieve immediate approval because it is not yet clear if the FDA is ready to use MRD as an endpoint for clinical trials.

Related Videos
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Related Content
Jan A. Burger, MD, PhD
July 25th 2024

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Matthew R. Cooperberg, MD, MPH, of UCSF
July 18th 2024

Prostate Cancer Test Is Missing Early Disease in Transgender Women

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Rahul Aggarwal, MD, of UCSF Helen Diller Family Comprehensive Cancer Center
July 11th 2024

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL
July 3rd 2024

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL